Skip to main content
Funded Studies

Michael A. Schwarzschild, MD, PhD

Professor of Neurology at Massachusetts General Hospital

Location: Boston, MA United States

Michael A. Schwarzschild, MD, PhD, is a neurologist at Massachusetts General Hospital and professor of neurology at Harvard Medical School. Dr. Schwarzschild’s research investigates genetic and environmental factors linked to Parkinson’s disease (PD) and translates insights gained from preclinical laboratory models to clinical trials. His group discovered the neuroprotective properties of caffeine and other adenosine A2A receptor blockers in mouse models of PD. Since 2012, he has led the Parkinson Study Group (PSG), a network of North American clinical trialists dedicated to improving therapy for people with PD.


Associated Grants

  • Perspective and Consensus on Prevention Planning for Parkinson’s Disease

    2022


  • Assessing the Potential of Low-Dose Carbon Monoxide Therapy in Parkinson’s Disease

    2021


  • Metabolomic Analysis of Penetrance, Prognosis and Tracking Biomarkers of LRRK2 PD

    2020


  • From Cancer Associations to Altered Immunity in the Pathogenesis of Parkinson’s Disease

    2020


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.